Multiple Ascending Oral Dose Study of F901318 in Healthy Subjects
Status:
Completed
Trial end date:
2017-05-22
Target enrollment:
Participant gender:
Summary
Double blind, placebo controlled, ascending multiple (10) oral dose, sequential group study.
Twenty-four subjects will complete the study in 3 cohorts (Groups A to C), each group
consisting of 8 subjects. Each cohort will consist of 4 male and 4 female subjects. Each
subject will be dosed for 10 days and will be on study for approximately 7 weeks. Each
subject will participate in one treatment cohort only, residing at the Clinical Research Unit
(CRU) from Day -1 (the day before dosing) to Day 15 (120 hours post the last dose). The dose
will range between 2 and 10 mg/kg daily, given as either a single daily dose or as two doses
divided over the 24-hour dosing period.
All subjects will return for a post-study visit 8 to 10 days after the last dose of study
medication.
Cohorts will be dosed at least at 3 weekly intervals. There will be a review of the safety
and pharmacokinetic data of each cohort prior to each dose escalation.